Literature DB >> 33930312

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.

Oliver Klein1, Damien Kee2, Ben Markman3, Matteo S Carlino4, Craig Underhill5, Jodie Palmer6, Daniel Power7, Jonathan Cebon8, Andreas Behren6.   

Abstract

Entities:  

Year:  2021        PMID： 33930312     DOI： 10.1016/j.ccell.2021.04.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  17 in total

1.  An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer.

Authors:  Guian Zhang; Yong Luo
Journal:  Int J Gen Med       Date:  2021-11-30

2.  Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.

Authors:  Daniel J McGrail; Patrick G Pilié; Hui Dai; Truong Nguyen Anh Lam; Yulong Liang; Leonie Voorwerk; Marleen Kok; Xiang H-F Zhang; Jeffrey M Rosen; Amy B Heimberger; Christine B Peterson; Eric Jonasch; Shiaw-Yih Lin
Journal:  Sci Transl Med       Date:  2021-10-27       Impact factor: 17.956

Review 3.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial.

Authors:  Alan J Korman; Sarah C Garrett-Thomson; Nils Lonberg
Journal:  Nat Rev Drug Discov       Date:  2021-12-22       Impact factor: 112.288

4.  Characterization of the Immune Cell Infiltration Landscape Uncovers Prognostic and Immunogenic Characteristics in Lung Adenocarcinoma.

Authors:  Xin Wang; Zhenyi Xu; Zhilin Liu; Weihao Lin; Zheng Cao; Xiaoli Feng; Yibo Gao; Jie He
Journal:  Front Genet       Date:  2022-05-23       Impact factor: 4.772

5.  A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective.

Authors:  Haili Bao; Yi Luo; Guoshan Ding; Zhiren Fu
Journal:  J Oncol       Date:  2022-05-07       Impact factor: 4.501

6.  The Clinical Prediction Value of the Ubiquitination Model Reflecting the Immune Traits in LUAD.

Authors:  Yinggang Che; Dongbo Jiang; Leidi Xu; Yuanjie Sun; Yingtong Wu; Yang Liu; Ning Chang; Jiangjiang Fan; Hangtian Xi; Dan Qiu; Qing Ju; Jingyu Pan; Yong Zhang; Kun Yang; Jian Zhang
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

7.  Comment on "Abscopal effect in the radio and immunotherapy".

Authors:  François Fabi
Journal:  Radiat Oncol J       Date:  2022-03-22

8.  Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.

Authors:  Qin Xu; Junjie Wang; Yang Sun; Yibin Lin; Jing Liu; Yanhong Zhuo; Zhangzhou Huang; Songhua Huang; Ying Chen; Li Chen; Meifang Ke; Li Li; Zirong Li; Junping Pan; Yanwen Song; Rongqiang Liu; Chuanben Chen
Journal:  J Clin Oncol       Date:  2022-02-22       Impact factor: 50.717

9.  Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Xiaoyan Meng; Zhonglong Liu; Lingfang Zhang; Yue He
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 10.  Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.

Authors:  Pratibha Pandey; Fahad Khan; Huda A Qari; Tarun Kumar Upadhyay; Abdulhameed F Alkhateeb; Mohammad Oves
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.